Moderna plans to seek authorization for its pediatric COVID-19 vaccine for kids 6 and under, but experts say the vaccine maker’s trials for the young age group raise too many questions.
VAERS data released Friday by the Centers for Disease Control and Prevention included a total of 1,205,755 reports of adverse events from all age groups following COVID vaccines, including 26,396 deaths and 214,521 serious injuries between Dec. 14, 2020, and March 25, 2022.
Just days after sparring with President Joe Biden’s nominee for the U.S. Supreme Court over her perceived leniency with child porn offenders, Sen. Josh...
A nurse at a middle school in Connecticut has reportedly been placed on leaveafter posting a comment on Facebook revealing that multiple young students at her public school were being treated as “non-binary,” most of them without the knowledge or permission of their parents.
The Defender’s Big Brother NewsWatch brings you the latest headlines related to governments’ abuse of power, including attacks on democracy, civil liberties and use of mass surveillance.
The Wall Street Journal this month published an article citing a flawed, unpublished study concluding ivermectin didn’t reduce COVID-19 hospitalizations. Meanwhile, the paper ignored news earlier this month that a documentary producer discovered the individual likely responsible for tanking a key, systematic review showing how ivermectin could have saved millions of lives.
In an appearance on “RFK Jr. The Defender Podcast,” Michael Nevradakis, Ph.D., a reporter for The Defender, explained how the two global asset giants pushing for vaccine passports also stand to profit greatly from orchestrating them.
A new peer-reviewed study shows more than two-thirds of adolescents with COVID-19 vaccine-related myopericarditis had persistent heart abnormalities months after their initial diagnosis, raising concerns for potential long-term effects and contradicting claims by health officials that the condition is “mild.”
U.S. regulators on Tuesday authorized another COVID-19 booster for people age 50 and older, a step to offer extra protection for the most vulnerable in case the coronavirus rebounds.
